Efficiency of conditionally attenuated Salmonella enterica serovar typhimurium in bacterium-mediated tumor therapy

mBio

Volumn 6, Issue 2, 2015, Pages 1-11

  Frahm, Michael ^a   Felgner, Sebastian ^a   Kocijancic, Dino ^a   Rohde, Manfred ^a   Hensel, Michael ^b   Curtiss, Iii Roy ^c   Erhardt, Marc ^a   Weiss, Siegfried ^a  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^b UNIVERSITY OF OSNABRÜCK   (Germany)

^c ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARABAD PROTEIN; BACTERIAL PROTEIN; MSBB PROTEIN; RFAD PROTEIN; RFAG PROTEIN; RFAH PROTEIN; RFAL PROTEIN; RFAP PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; LIPOPOLYSACCHARIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARABAD GENE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GENE; BACTERIAL LOAD; BACTERIAL VIRULENCE; CANCER GENE THERAPY; COLORECTAL CANCER; COMPLEMENT SYSTEM; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; FIBROSARCOMA; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; KIDNEY CARCINOMA; MOUSE; MSBB GENE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; RFAD GENE; RFAG GENE; RFAH GENE; RFAL GENE; RFAP GENE; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL THERAPY; DEFICIENCY; DISEASE MODEL; GENE DELETION; GENE EXPRESSION REGULATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLIC ENGINEERING; NEOPLASMS; PROCEDURES; TRANSGENIC ORGANISM; VIRULENCE;

BACTERIA (MICROORGANISMS); SALMONELLA; SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM; SALMONELLA TYPHIMURIUM;

ANIMALS; BIOLOGICAL THERAPY; DISEASE MODELS, ANIMAL; GENE DELETION; GENE EXPRESSION REGULATION, BACTERIAL; LIPOPOLYSACCHARIDES; METABOLIC ENGINEERING; MICE, INBRED BALB C; NEOPLASMS; ORGANISMS, GENETICALLY MODIFIED; SALMONELLA TYPHIMURIUM; VIRULENCE;

EID: 84928796820     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00254-15     Document Type: Article

References (33)

1. Couzin-Frankel J.2013. Cancer immunotherapy. Scientist 342: 1432-1433. http://dx.doi.org/10.1126/science.342.6165.1432.
2. Ito F, Chang AE. 2013. Cancer immunotherapy: current status and future directions. Surg Oncol Clin N Am 22:765-783. http://dx.doi.org/10.1016/j.soc.2013.06.005.
3. Coley WB. 1898. The treatment of inoperable sarcoma with the’mixed toxins of Erysipelas and Bacillus prodigiosus. Immediate and final results in one hundred and forty cases. J Am Med Assoc 31:389-395.
4. Nauts HC, Fowler GA, Bogatko FH. 1953. A review of the influence of bacterial infection and of bacterial products (Coley’s toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley’s mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study. Acta Med Scand Suppl 276:1-103.
5. Nauts HC, McLaren JR. 1990. Coley toxins—the first century, p 483-500. In Bicher HI, McLaren JR, PigliucciGM(ed), Consensus on hyperthermia for the 1990s: Clinical practice in cancer treatment. Springer, New York, NY.
6. Choe E, Kazmierczak RA. 2014. Phenotypic evolution of therapeutic Salmonella enterica serovar Typhimurium after invasion of TRAMP mouse prostate tumor. mBio 5(4):e01182-14. http://dx.doi.org/10.1128/mBio.01182-14.
7. Krick EL, Sorenmo KU, Rankin SC, Cheong I, Kobrin B, Thornton K, Kinzler KW, Vogelstein B, Zhou S, Diaz LA. 2012. Evaluation of Clostridium novyi-NT spores in dogs with naturally occurring tumors. Am J Vet Res 73:112-118. http://dx.doi.org/10.2460/ajvr.73.1.112.
8. Roberts NJ, Zhang L, Janku F, Collins A, Bai R-Y, Staedtke V, Rsk AW, Tung D, Miller M, Roix J, Khanna KV, Murthy R, Benjamin RS, Helgason T, Szvalb AD, Bird JE, Roy-Chowdhuri S, Zhang HH, Qiao Y, Karim B, McDaniel J, Elpiner A, Sahora A, Lachowicz J, Phillips B, Turner A, Klein MK, Post G, Diaz LA, Riggins GJ, Papadopoulos N, Kinzler KW, Vogelstein B, Bettegowda C, Huso DL, Varterasian M. Saha S, Zhou S. 2014. Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses. Sci Transl Med 6:249ra111. http://dx.doi.org/10.1126/scitranslmed.3008982.
9. Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, Sherry RM, Topalian SL, Yang JC, Stock F, Freezer LJ, Morton KE, Seipp C, Haworth L, Mavroukakis S, White D, MacDonald S, Mao J, Sznol M, Rosenberg SA. 2002. Phase I study of the intravenous administration of attenuated Salmonella Typhimurium to patients with metastatic melanoma. J Clin Oncol 20:142-152. http://dx.doi.org/10.1200/JCO.20.1.142.
10. Forbes NS. 2010. Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer 10:785-794. http://dx.doi.org/10.1038/nrc2934.
11. Zhao M, Yang M, Ma H, Li X, Tan X, Li S, Yang Z, Hoffman RM. 2006. Targeted therapy with a Salmonella Typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res 66:7647-7652. http://dx.doi.org/10.1158/0008-5472.CAN-06-0716.
12. Leschner S, Westphal K, Dietrich N, Viegas N, Jablonska J, Lyszkiewicz M, Lienenklaus S, Falk W, Gekara N, Loessner H, Weiss S. 2009. Tumor invasion of Salmonella enterica serovar Typhimurium is accompanied by strong hemorrhage promoted by TNF-α. PLoS One 4:e6692. http://dx.doi.org/10.1371/journal.pone.0006692.
13. Chorawala MR, Oza PM, Trivedi VR, Deshpande SS, Shah GB. 2013. Lipopolysaccharides: An overview. World Journal of Pharmacy and Pharmaceutical Sciences 2:465-477.
14. Kong Q, Six DA, Roland KL, Liu Q, Gu L, Reynolds CM, Wang X, Raetz CR, Curtiss R. 2011. Salmonella synthesizing 1-dephosphorylated lipopolysaccharide exhibits low endotoxic activity while retaining its immunogenicity. J Immunol 187:412-423. http://dx.doi.org/10.4049/jimmunol.1100339.
15. Kong Q, Yang J, Liu Q, Alamuri P, Roland KL, Curtiss R. 2011. Effect of deletion of genes involved in lipopolysaccharide core and O-antigen synthesis on virulence and immunogenicity of Salmonella enterica serovar Typhimurium. Infect Immun 79:4227-4239. http://dx.doi.org/10.1128/IAI.05398-11.
16. Aachoui Y, Leaf IA, Hagar JA, Fontana MF, Campos CG, Zak DE, Tan MH, Cotter PA, Vance RE, Aderem A, Miao EA. 2013. Caspase-11 protects against bacteria that escape the vacuole. Science 339:975-978. http://dx.doi.org/10.1126/science.1230751.
17. Westphal K, Leschner S, Jablonska J, Loessner H, Weiss S. 2008. Containment of tumor-colonizing bacteria by host neutrophils. Cancer Res 68:2952-2960. http://dx.doi.org/10.1158/0008-5472.CAN-07-2984.
18. Leschner S, Weiss S. 2010. Salmonella—allies in the fight against cancer. J Mol Med (Berl) 88:763-773. http://dx.doi.org/10.1007/s00109-010-0636-z.
19. Zenk SF, Jantsch J, Hense lM. 2009. Role of Salmonella enterica lipopolysaccharide in activation of dendritic cell functions and bacterial containment. J Immunol 183:2697-2707. http://dx.doi.org/10.4049/jimmunol.0900937.
20. Kasinskas RW, Forbes NS. 2007. Salmonella Typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis. Cancer Res 67:3201-3209. http://dx.doi.org/10.1158/0008-5472.CAN-06-2618.
21. Crull K, Bumann D, Weiss S. 2011. Influence of infection route and virulence factors on colonization of solid tumors by Salmonella enterica serovar Typhimurium. FEMS Immunol Med Microbiol 62:75-83. http://dx.doi.org/10.1111/j.1574-695X.2011.00790.x.
22. Stritzker J, Weibel S, Seubert C, Götz A, Tresch A, van Rooijen N, Oelschlaeger TA, Hill PJ, Gentschev I, Szalay AA. 2010. Enterobacterial tumor colonization in mice depends on bacterial metabolism and macrophages but is independent of chemotaxis and motility. Int J Med Microbiol 300:449-456. http://dx.doi.org/10.1016/j.ijmm.2010.02.004.
23. Kaimala S, Mohamed YA, Nader N, Issac J, Elkord E, Chouaib S, Fernandez-Cabezudo MJ, Al-Ramadi BK. 2014. Salmonella-mediated tumor regression involves targeting of tumor myeloid suppressor cells causing a shift to M1-like phenotype and reduction in suppressive capacity. Cancer Immunol Immunother 63:587-599. http://dx.doi.org/10.1007/s00262-014-1543-x.
24. Lee C-H, Wu C-L, Shiau A-L. 2008. Toll-like receptor 4 mediates an antitumor host response induced by Salmonella choleraesuis. Clin Cancer Res 14:1905-1912. http://dx.doi.org/10.1158/1078-0432.CCR-07-2050.
25. Swartz MA, Lund AW. 2012. Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity. Nat Rev Cancer 12:210-219. http://dx.doi.org/10.1038/nrc3186.
26. Hoiseth SK, Stocker BA. 1981. Aromatic-dependent Salmonella Typhimurium are non-virulent and effective as live vaccines. Nature 291: 238-239. http://dx.doi.org/10.1038/291238a0.
27. Kong Q, Liu Q, Jansen AM, Curtiss R. 2010. Regulated delayed expression of rfc enhances the immunogenicity and protective efficacy of a heterologous antigen delivered by live attenuated Salmonella enterica vaccines. Vaccine 28:6094-6103. http://dx.doi.org/10.1016/j.vaccine.2010.06.074.
28. Kong Q, Liu Q, Roland KL, Curtiss R. 2009. Regulated delayed expression of rfaH in an attenuated Salmonella enterica serovar Typhimurium vaccine enhances immunogenicity of outer membrane proteins and a heterologous antigen. Infect Immun 77:5572-5582. http://dx.doi.org/10.1128/IAI.00831-09.
29. Loessner H, Leschner S, Endmann A, Westphal K, Wolf K, Kochruebe K, Miloud T, Altenbuchner J, Weiss S. 2009. Drug-inducible remote control of gene expression by probiotic Escherichia coli Nissle 1917 in intestine, tumor and gall bladder of mice. Microbes Infect 11:1097-1105. http://dx.doi.org/10.1016/j.micinf.2009.08.002.
30. Bauer H, Darji A, Chakraborty T, Weiss S. 2005. Salmonella-mediated oral DNA vaccination using stabilized eukaryotic expression plasmids. Gene Ther 12:364-372. http://dx.doi.org/10.1038/sj.gt.3302423.
31. Karlinsey JE. 2007. Lambda-red genetic engineering in Salmonella enterica serovar Typhimurium. Methods Enzymol 421:199-209. http://dx.doi.org/10.1016/S0076-6879(06)21016-4.
32. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A 97:6640-6645. http://dx.doi.org/10.1073/pnas.120163297.
33. Gahring LC, Heffron F, Finlay BB, Falkow S. 1990. Invasion and replication of Salmonella typhimurium in animal cells. Infect Immun 58: 443-448.